Pancreatic Cancer Research

ResearcherWashington University in St. LouisNo recent work listed

Todd S. Crocenzi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8762-1990; OpenAlex author ID A5079825829. Sources: OpenAlex.

Their work

Papers
6 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper

Papers 6

  1. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-19-3978↗
  2. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  3. A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pa… Co-author DOI 10.1186/s40425-016-0149-6↗
  4. Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patient… First author DOI 10.1186/2051-1426-3-s2-p155↗
  5. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Co-author DOI 10.1200/jco.2014.57.4244↗
  6. A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with pre… Co-author DOI 10.1186/2051-1426-2-s3-p68↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dung Thi Le · 5 shared papers, 2014–2020 · strength 0.27
  2. Dirk G. Brockstedt · 5 shared papers, 2014–2020 · strength 0.27
  3. Elizabeth M. Jaffee · 5 shared papers, 2014–2020 · strength 0.27
  4. Andrew H. Ko · 3 shared papers, 2015–2020 · strength 0.20
  5. Daniel A. Laheru · 3 shared papers, 2015–2020 · strength 0.16
  6. Herbert J. Zeh · 3 shared papers, 2014–2019 · strength 0.14
  7. Andrea Wang‐Gillam · 3 shared papers, 2014–2019 · strength 0.14
  8. Vincent J. Picozzi · 3 shared papers, 2014–2019 · strength 0.14
  9. Robert H. Vonderheide · 2 shared papers, 2015–2020 · strength 0.13
  10. George Albert Fisher · 2 shared papers, 2015–2020 · strength 0.13
  11. Michael Andrew Morse · 2 shared papers, 2015–2019 · strength 0.11
  12. Lisa M. Coussens · 1 shared paper, 2020 · strength 0.08
  13. Robert A. Anders · 1 shared paper, 2020 · strength 0.08
  14. Elana Judith Fertig · 1 shared paper, 2020 · strength 0.08
  15. Annie A. Wu · 1 shared paper, 2020 · strength 0.08
  16. Takahiro Tsujikawa · 1 shared paper, 2020 · strength 0.08
  17. Margaret A. Tempero · 1 shared paper, 2020 · strength 0.08
  18. Kim A. Reiss · 1 shared paper, 2020 · strength 0.08
  19. Eric R. Lutz · 2 shared papers, 2015 · strength 0.08
  20. Robert Lance Fine · 2 shared papers, 2014–2015 · strength 0.07
  21. Zev A. Wainberg · 1 shared paper, 2019 · strength 0.07
  22. Dan A. Laheru · 1 shared paper, 2019 · strength 0.07
  23. Noelle K. LoConte · 1 shared paper, 2019 · strength 0.07
  24. Nitya Nair · 1 shared paper, 2019 · strength 0.07
  25. Chan C. Whiting · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.